Phase II Pilot Study Assessing Efficacy of a Cisplatin - Metronomic Cyclophosphamide Treatment in Patients With Metastatic Triple Negative Breast Cancer Resistant to Anthracyclines and Taxanes

NCT01910870 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped Because of difficulties in recruiting

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Cisplatin
DRUG: Metronomic Cyclophosphamide

Sponsor

Centre Jean Perrin